NAGE Company Profile and Key Details

Niagen Bioscience Inc has 79.81 million shares outstanding. The public float is 52.72 million shares, elevated short interest at 12.31% of float. This equals 6.49 million shares. The short ratio is 7.82 days. Institutional investors hold 63.5% of the float. Insiders own 33.89%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Short-term trend indicators are bullishly aligned (SMA20 -2.13%, SMA50 -13.03%, SMA200 -39.92%). The stock’s 14-day RSI is 41.17 (neutral), while the ATR of 0.26 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -64.74% below its high and over 9.35% above its low. Average 10-day trading volume of 727.09 thousand shares is below the 3-month average of 1.01 million, indicating normal recent market interest.

Niagen Bioscience Inc (NASDAQ:NAGE) closed at $4.93 USD, gaining $0.08 (1.65%) from the previous close of $4.85. The stock is currently mid-range between its 52-week high and low $4.16 and $14.69. With a market capitalization of about $394.80 million, Niagen Bioscience Inc is classified as a small-cap and shows higher-than-market volatility (beta ~2.23). Key stats such as the average daily volume over the past year has been around 1.16 million shares, in line with its 52-week average. Headquartered in Los Angeles, CA, Niagen Bioscience Inc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert N. Fried, the company employs approximately 104 people and listed since June 24, 2015. Niagen Bioscience Inc is a bioscience company dedicated to healthy aging.

Wall Street analysts project EPS growth of 53.78% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $23.00 to $12.00. The high target offers 366.53% upside. The low target suggests 143.41% downside. The mean target is $15.20. This offers 208.32% upside. Niagen Bioscience Inc earnings surprise history is a consistent trend of beating forecasts. The quarter that ended March 04, 2026, missed forecasts by 50.0%. The prior quarter beat by 368.47%. Over the last six quarters, Apple has recorded several small beats. These include 100.0% in October 31, 2024.

Niagen Bioscience Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.51. This means the shares are trading below this model’s fair value.

Niagen Bioscience Inc (NASDAQ:NAGE) shares are flat -2.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Niagen Bioscience Inc trading at a premium to the broader market with a P/E of 22.45. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.00, suggesting 183.98% upside. Our AI forecast model points to short-term strength (4.46% over two weeks), a medium-term fall (-3.65% over three months), and a longer-term loss (-54.36% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Niagen Bioscience Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.46%, with price expected at $5.15 by May 18, 2026, within a range of $5.00 to $5.30 3-Month Outlook: Projected fall of -3.65%, reaching $4.75 by July 31, 2026, with a range of $4.61 to $4.90. 1-Year Outlook: Projected loss of -54.36%, with price at $2.25 by May 04, 2027, within a range of $2.07 to $2.37.

Niagen Bioscience Inc trades at a P/E ratio of 22.45, slightly below the S&P 500 average, with a price-to-sales ratio of 3.06 and a price-to-book ratio of 5.1 trading at moderately above to book value. The P/FCF stands at 30.08, also above market averages.